As sales of blockbuster drug Acthar begins to crack Mallinckrodt (MNK) is in desperate need of a new narrative. Management is trying to sell investors on the idea that it can generate new products from its R&D pipeline. In the meantime it is also looking to diversify its revenue and earnings stream via acquisition. Last week Mallinckrodt announced the $1.2 billion acquisition of Sucampo Pharmaceuticals (SCMP). Sucampo’s primary product, Amitiza (lubiprostone), treats chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation (IBS-C) in adult women and opioid-induced constipation (OIC) in adults suffering from chronic non-cancer related pain.

Sucampo had Q3 revenue of $61 million and EBITDA of $29 million. The transaction is attractively priced at about 9.2x run-rate EBITDA. The deal is all cash and Mallinckrodt will likely have to incur over $800 million of new debt to fund the acquisition. Therein lies the rub.

Moody’s Puts Mallinckrodt On Watch For A Downgrade

Prior to the deal Mallinckrodt’s debt/run-rate EBITDA exceeded 4x. New debt to fund the transaction will make the company even more highly-indebted during a time when Mallinckrodt’s core business is appears to be weakening. Moody’s recently put the company’s debt under review for a downgrade:

Moody’s Investors Service (“Moody’s”) placed the ratings of Mallinckrodt International Finance SA (“Mallinckrodt”), including the Ba3 Corporate Family Rating and Ba3-PD Probability of Default Rating, under review for downgrade. The SGL-2 Speculative Grade Liquidity Rating was affirmed.

This action follows today’s announcement that Mallinckrodt will acquire Sucampo Pharmaceuticals (unrated) for a total purchase price of $1.2 billion. The deal will be funded with a mix of bank revolver borrowings and term loan debt and/or cash …

The acquisition of Sucampo increases Mallinckrodt’s gross debt/EBITDA to around 4.9 times on a pro forma basis from around 4.4 times (LTM September 30, 2017) and reduces its financial flexibility. Mallinckrodt also faces earnings pressure in its specialty generics segment and sales growth headwinds in 2018 on its largest drug, Acthar.